Myocardial infarction and viral triggers: what do we know by now?

被引：10
作者：
Caldeira, Daniel [1 ,2 ,3 ,4 ]
Nogueira-Garcia, Beatriz [1 ,2 ]
机构：
[1] Univ Lisbon, Ctr Cardiovasc Univ Lisboa CCUL, Fac Med, CAML, Lisbon, Portugal
[2] Hosp Univ Santa Maria CHULN, Cardiol Dept, Lisbon, Portugal
[3] Univ Lisbon, Fac Med, Lab Clin Pharmacol & Therapeut, Ave Prof Egas Moniz, P-1649028 Lisbon, Portugal
[4] Univ Lisbon, Fac Med, Ctr Estudos Med Baseada Evidencia CEMBE, Lisbon, Portugal
来源：
EUROPEAN HEART JOURNAL SUPPLEMENTS | 2023年 / 25卷
关键词：
Acute coronary syndrome; Influenza vaccine; COVID-19; Troponin; Myocardial injury; HERPES-SIMPLEX-VIRUS; CARDIOVASCULAR-DISEASE; INFLUENZA VACCINATION; ACUTE INFECTION; RISK; CYTOMEGALOVIRUS; BURDEN; DEATH;
D O I：
10.1093/eurheartjsupp/suac122
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Myocardial infarction (MI) is an acute clinical manifestation ischaemic heart disease, which is the leading cause of death worldwide. Infections also have an important burden worldwide, with lower respiratory infections being the worldwide leading cause of death due to communicable diseases. The relationship of MI with viral respiratory infections (including influenza and SARS-CoV-2) as a trigger has been well documented with significant associations. These infections can lead to Type 1 MI, where inflammation and vascular dysfunction, as well as the increased prothrombotic environment lead to atherothrombosis. Type 2 MI may also occur due to an imbalance of oxygen/blood supply and myocardial demand (hypoxaemia, fever, and tachycardia). The data from randomized controlled trials showing a potential benefit of influenza vaccination in coronary artery disease patients should not be ignored. This can be considered a further argument for the association of viral infections (influenza in particular) and MI.
引用
收藏
页码：A12 / A16
页数：5
相关论文
共 50 条
[31]   MENOPAUSAL HORMONE THERAPY: WHAT WE KNOW NOW [J].
Roush, Karen .
AMERICAN JOURNAL OF NURSING, 2011, 111 (06) :38-47
[32]   Environment, Climate and Cardiovascular Health: What We Know, What We Need to Know and What We Need to Do [J].
Redfern, Julie ;
Gregory, Ann T. ;
Raman, Jai ;
Figtree, Gemma A. ;
Singleton, Anna ;
Denniss, Robert ;
Ferguson, Caleb .
HEART LUNG AND CIRCULATION, 2023, 32 (01) :1-3
[33]   Cardiac biomarkers in patients suspected of acute myocardial infarction: Where do we stand and where do we go? [J].
Meune, Christophe ;
Aiessou, Linda ;
Sorbets, Emmanuel .
ARCHIVES OF CARDIOVASCULAR DISEASES, 2014, 107 (12) :643-645
[34]   Contralateral Prophylactic Mastectomy: What Do We Know and What Do Our Patients Know? [J].
Khan, Seema A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) :2132-2135
[35]   Sudden Cardiac Death in the Young: What We Know, What We Don't Know and What We Need To Do [J].
Vohra, Jitendra .
HEART LUNG AND CIRCULATION, 2014, 23 (12) :1097-1099
[36]   What do we know about lipoprotein(a)? [J].
Cybulska, Barbara ;
Klosiewicz-Latoszek, Longina .
KARDIOLOGIA POLSKA, 2015, 73 (04) :235-239
[37]   Merkel cell carcinoma: What do we know about it and what should we do? [J].
Prieto Munoz, Isabel ;
Pardo Masferrer, Jose ;
Olivera Vegas, Jesus ;
Fortes Alen, Jose Ramon ;
Perez Casas, Ana M. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (06) :401-412
[38]   COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know [J].
Dhawan, Rahul ;
Gundry, Rebekah L. ;
Brett-Major, David M. ;
Mahr, Claudius ;
Thiele, Geoffrey M. ;
Lindsey, Merry L. ;
Anderson, Daniel R. .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2020, 144 :12-14
[39]   Productive effects of public works programs: What do we know? What should we know? [J].
Gehrke, Esther ;
Hartwig, Renate .
WORLD DEVELOPMENT, 2018, 107 :111-124
[40]   What do we do now? Implications for the clinical practice [J].
DePaolis, Michael .
CONTACT LENS & ANTERIOR EYE, 2013, 36 :S28-S33
12345